Tenderwize
Wróć do wyszukiwania

Non-exclusive drug discount agreement for Tiotropium bromide

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Dec 31, 2026 · 126 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Tiotropium bromid (ATC-Code nach WHO: R03BB04)

20/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

20 / 100

Złożoność

30 / 100

Czynniki ryzyka

No guaranteed minimum purchase volumes. Revenue is uncertain and depends on physician prescription behavior and patient...

The buyer may terminate the open-house model early if exclusive agreements are concluded, which could happen within 8–1...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Conclude a non-exclusive drug discount agreement for Tiotropium bromide under §130a Abs. 8 SGB V.
  • The agreement is open to all interested pharmaceutical companies that meet the participation requirements.
Pokaż pełne podsumowanie

This is an open-house model for non-exclusive drug discount agreements (Rabattvereinbarungen) for the active substance Tiotropium bromide (ATC R03BB04). The AOK PLUS health insurance fund invites any pharmaceutical company that meets the conditions to sign a non-negotiable discount agreement. There is no exclusivity, no guaranteed purchase volumes, and the agreement ends by 31.12.2026. Participation applications can be submitted periodically, with the first deadline on 03.12.2024. The tender is governed by German social law (§130a Abs. 8 SGB V) and is not a public procurement under EU directives; the use of procurement forms is for transparency only.

Ryzyka

No guaranteed minimum purchase volumes. Revenue is uncertain and depends on physician prescription behavior and patient...

The buyer may terminate the open-house model early if exclusive agreements are concluded, which could happen within 8–1...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical company as defined in §4 Abs. 18 AMG for the offered medicinal products.
  • Company must have its seat in Germany, EU, or EEA.

Eligibility

  • Submit a declaration of no exclusion grounds under §§123, 124 GWB (using the provided form).

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive drug discount agreement for Tiotropium bromide

Open-house model for concluding non-exclusive discount agreements on Tiotropium bromide. Any qualifying pharmaceutical company can participate. No negotiations, no exclusivity, no minimum purchase quantities. The agreement term runs until 31.12.2026.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Dec 2024 - Dec 2026

Kategoria

Pharmaceutical products

Termin

Expired Dec 03, 2024

Szczegóły zamówienia

Data publikacji
10 Nov 2024
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
684322-2024

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3